Amgen names Piacquad senior VP of business development

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Amgen names Piacquad senior VP of business development

Amgen ($AMGN) appointed David Piacquad to be its new senior vice president of business development. Formerly the company's vice president of strategy and corporate development, Piacquad has also spent time at Schering-Plough and Johnson & Johnson ($JNJ) in the finance and business development sectors. Release

Amgen
David Piacquad will be Amgen's VP of business development.


Novimmune
Andrew Oakley will be the new CFO.


Biotech

> Novimmune appointed Andrew Oakley as its chief financial officer. Release

> Japan's Eisai named Yuji Matsue as chairman and chief executive officer and Shaji Procida as president and chief operating officer, succeeding current president and CEO Lonnel Coats, who is retiring in June. Release

> Hologic ($HOLX) said goodbye to CFO Glenn Muir, retiring after 25 years with the company. Eric Compton, formerly of J&J's Ortho Clinical Diagnostics, joins as chief operating officer, a newly established role. Claus Egstrand is promoted to senior VP and general manager. David Harding is now senior VP of corporate strategy. Story

> Sorrento Therapeutics ($SRNE) has added Mark Durand to its board of directors. Release

> BioNano Genomics has appointed Joel Jung as chief financial officer. Release

> Synergy Pharmaceuticals ($SGYP) announced this week the appointment of Marino Garcia as senior vice president of corporate development. Release

> Tetraphase Pharmaceuticals ($TTPH) has added Nancy Wysenski to the company's board of directors. Release

> Inergetics appointed Joseph McSherry to its scientific/medical advisory board for the development of cannabidiol-based nutritional supplements. Release

> Intrexon ($XON) named Kelly Huang as the head of its consumer sector. Release

> Intra-Cellular Therapies appointed Dr. Juan Sanchez as its vice president of corporate communications and investor relations. Release

> Pernix Therapeutics appointed Terence Novak as its chief operating officer. Release

> Harvard Bioscience named Ronald Aplin its vice president of global operations and quality. Release

> Novavax ($NVAX) appointed John Trizzino as its senior vice president of commercial operations. Release

> Diane Corrado joined Decision Resources Group as its executive vice president of sales and marketing. Release

Pharma

Avion Pharmaceuticals named Mike Sullivan president. Release

> Vince Ippolito joined Anacor Pharmaceuticals ($ANAC) as the company's chief commercial officer. Release

CRO

> Novella Clinical, a Quintiles ($Q) company, has appointed Chris Smyth as managing director of European and Asian operations. Release

> Camargo Pharmaceutical Services has added Olu Aloba to the team as senior director of pharmaceutics. Release

Biotech IT

> PHT has promoted Dr. Susan Dallabrida to vice president of clinical science and consulting services. Release

Diagnostics

> Caliber Imaging & Diagnostics, formerly Lucid, has named Daniel Koon to director of global sales support. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.